The Food and Drug Administration has approved expanded use of leucovorin calcium tablets for treating cerebral folate deficiency, a rare disorder.
14h
FDA approves Wellcovorin for ultra-rare disease. The Trump admin touted it as a treatment for autism
The Food and Drug Administration (FDA) on Tuesday granted expanded approval to Wellcovorin for the ultra-rare disease cerebral folate deficiency (CFD) in both children and adults, the same ...
Cerebral folate deficiency is a rare neurological disorder characterized by a decrease in CSF folate levels, leading to developmental regression, seizures, movement disorders, and other neurological ...
About five months after U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. | About five months after U.S. Health Secretary Robert F. Kennedy Jr. touted leucovorin as “an ...
Prenatal care is essential for the health of expectant mothers and newborns alike. The U.S. Department of Health & Human Services Office on Women's Health notes that babies of mothers who don't get ...
The latest psychiatry journals are absolutely hopping with trials of folic acid and its downstream metabolite, methylfolate. We have this article from AJP, this one from JAMA Archives, along with ...
August 1, 2024 - by Ashley Vargo - In a study published in Life Science Alliance, Texas A&M AgriLife Research scientists found that decreasing folate intake can support healthier metabolisms in aging ...
I remember first learning about folic acid maybe 15 years ago in school. Unless you were a chemist "folic acid" and "folate" were pretty much interchangeable words – except that folate was the form of ...
In the past, Recommended Dietary Allowances (RDAs) were the primary values available to health professionals for planning and assessing the diets of individuals and groups and for making judgments ...
The FDA has expanded its approval of leucovorin calcium tablets to treat cerebral folate deficiency in patients with a folate receptor 1 gene variant, according to a press release from the agency.
FDA granted a narrow indication for CFD-FOLR1, targeting impaired folate transport into the CNS that drives developmental delay, seizures, movement disorders, and autistic features in some patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results